ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, the same mechanism of STAT activation via BCR-ABL was also observed in CML treated with pimazode, which deactivated STAT5 by inhibiting tyrosine kinase activity of BCR-ABL [89].